Novartis AG

What they do

Novartis researches, develops, manufactures and markets innovative prescription medicines across therapeutic areas that include cardiovascular, renal and metabolic, oncology and neuroscience. The company reports geographic revenue across the United States, China, Germany and other countries, with additional regional splits for Europe, Asia/Africa/Australasia, Canada and Latin America, and Established versus Emerging Growth Markets. Its largest reported product-level disclosure in the excerpts is Entresto, within the Cardiovascular, Renal and Metabolic area. The 2023 divestment of Sandoz, classified as discontinued operations, means the continuing business is the innovative-medicines operation.

Revenue drivers

• Entresto (cardiovascular, renal and metabolic) — Entresto is disclosed as part of the Cardiovascular, Renal and Metabolic therapeutic area, making it one of the named product lines in the filing excerpts.
• United States sales — The U.S. is a separately reported country in the revenue disaggregation, alongside China and Germany, indicating it is a primary commercial market.
• Established Markets — Revenue is split between Established Markets and Emerging Growth Markets, with Established Markets reported separately from Europe, Asia/Africa/Australasia, Canada and Latin America.
• Emerging Growth Markets — Reported as a separate revenue grouping from Established Markets, covering the company's business in faster-growing markets outside the established regions.

Recent performance

The filing excerpts do not present a full income statement, but the equity statement shows three consecutive annual reporting periods: 2023, 2024 and 2025, all with continuing operations results. The company reports revenue disaggregated by country, region, Established versus Emerging Growth Markets, and by therapeutic area including Cardiovascular, Renal and Metabolic with the Entresto product line. No specific revenue, growth or profit figures are recoverable from the text provided, which consists primarily of XBRL taxonomy tags rather than narrative discussion. The disclosures also show 2023 Sandoz results reported within discontinued operations.

Strategy

Novartis has been an active acquirer of clinical-stage biotech assets, with disclosed transactions including Kate Therapeutics (October 2024), Mariana Oncology (May 2024), MorphoSys AG (May 2024), DTx Pharma (July 2023) and Chinook Therapeutics (August 2023). More recent transactions in the excerpts include Tourmaline Bio (October 2025), a private clinical-stage biotech company (September 2025), Regulus Therapeutics (June/July 2025) and Anthos Therapeutics (April 2025). These deals involved acquired research and development and other intangible assets, indicating a focus on adding pipeline programs through acquisitions. The 2023 separation of Sandoz, classified as discontinued operations, reflects a strategic concentration on innovative medicines.

Risks

• Pipeline execution and acquisition integration — Novartis has completed multiple acquisitions of clinical-stage companies, including MorphoSys, Chinook, Kate Therapeutics, Mariana Oncology, Anthos, Regulus and Tourmaline Bio, creating integration and development risk on acquired programs.
• Revenue concentration in named products and markets — The filing identifies Entresto within Cardiovascular, Renal and Metabolic and discloses revenue by individual countries, indicating dependence on a limited set of products and geographies.
• Customer concentration — The excerpts separately identify largest, second-largest and third-largest customers, indicating a portion of revenue is concentrated among a small number of customers.
• Emerging market and geographic volatility — Revenue is split into Established Markets, Emerging Growth Markets, and separate regions including China, Europe, Asia/Africa/Australasia and Canada/Latin America, exposing results to differing local conditions.

Outlook

The excerpts do not contain a management outlook, guidance or forward-looking narrative discussion. The disclosed activity consists mainly of acquisitions and the Sandoz separation, with no quantified forward targets, timelines or projections recoverable from the text. As a result, no specific outlook statement can be attributed to management from these excerpts.